Risankizumab (ABBV-066) is an anti-IL-23 antibody approved for the treatment of multiple inflammatory diseases, including psoriasis, psoriatic arthritis, and Crohn's disease. It is also being investigator for the treatment of ulcerative colitis.
Type of MoleculeBiologic
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted)|
|Crohn's Disease||US - Approved,EU - Submitted||